Literature DB >> 12752260

Genetic control of susceptibility to spontaneous testicular germ cell tumors in mice.

Man-Yee Josephine Lam1, Joseph H Nadeau.   

Abstract

Testicular germ cell tumors (TGCTs) are the most common cancer affecting young men. TGCT is a polygenic trait and genes that control susceptibility for TGCT development have not yet been identified. The 129/Sv inbred strain of mice is an important experimental model to study the genetics and development of TGCTs. We review several novel approaches that were developed to study the susceptibility of TGCTs in the 129/Sv mouse model and its application in humans. These approaches showed that several spontaneous and engineered mutations interact with 129/Sv-derived susceptibility genes to enhance or suppress susceptibility; two of these mutations (Ter and Trp53) revealed novel linkages for susceptibility genes in sensitized polygenic trait analysis. Linkage analysis with a chromosome substitution strains suggests that as many as 100 genes control susceptibility. Bilateral TGCTs result from the coincidental occurrence of unilateral tumors. These results highlight the important contributions that this mouse model can make to studies of TGCT susceptibility in humans.

Entities:  

Mesh:

Year:  2003        PMID: 12752260     DOI: 10.1034/j.1600-0463.2003.11101221.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  14 in total

Review 1.  Epigenetic reprogramming and induced pluripotency.

Authors:  Konrad Hochedlinger; Kathrin Plath
Journal:  Development       Date:  2009-02       Impact factor: 6.868

Review 2.  Cell-intrinsic reprogramming capability: gain or loss of pluripotency in germ cells.

Authors:  Masanori Imamura; Zachary Yu-Ching Lin; Hideyuki Okano
Journal:  Reprod Med Biol       Date:  2012-06-19

3.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

Review 4.  p53 connects tumorigenesis and reprogramming to pluripotency.

Authors:  Natalia Tapia; Hans R Schöler
Journal:  J Exp Med       Date:  2010-09-27       Impact factor: 14.307

5.  Interaction between DMRT1 function and genetic background modulates signaling and pluripotency to control tumor susceptibility in the fetal germ line.

Authors:  Anthony D Krentz; Mark W Murphy; Teng Zhang; Aaron L Sarver; Sanjay Jain; Michael D Griswold; Vivian J Bardwell; David Zarkower
Journal:  Dev Biol       Date:  2013-03-06       Impact factor: 3.582

6.  BAX-mediated cell death affects early germ cell loss and incidence of testicular teratomas in Dnd1(Ter/Ter) mice.

Authors:  Matthew S Cook; Douglas Coveney; Iordan Batchvarov; Joseph H Nadeau; Blanche Capel
Journal:  Dev Biol       Date:  2009-02-06       Impact factor: 3.582

7.  Loss of the transmembrane but not the soluble kit ligand isoform increases testicular germ cell tumor susceptibility in mice.

Authors:  Jason D Heaney; Man-Yee J Lam; Megan V Michelson; Joseph H Nadeau
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

8.  Enhancers and suppressors of testicular cancer susceptibility in single- and double-mutant mice.

Authors:  Man-Yee Josephine Lam; Kirsten K Youngren; Joseph H Nadeau
Journal:  Genetics       Date:  2004-02       Impact factor: 4.562

9.  Analysis of chromatin accessibility in p53 deficient spermatogonial stem cells for high frequency transformation into pluripotent state.

Authors:  Sitong Liu; Rui Wei; Hongyang Liu; Ruiqi Liu; Pengxiao Li; Xiaoyu Zhang; Wei Wei; Xiaodong Zhao; Xiaomeng Li; Yang Yang; Xueqi Fu; Kang Zou
Journal:  Cell Prolif       Date:  2022-02-04       Impact factor: 6.831

10.  Nanog retrotransposed genes with functionally conserved open reading frames.

Authors:  Morag Robertson; Frances Stenhouse; Douglas Colby; Jamie R K Marland; Jennifer Nichols; Susan Tweedie; Ian Chambers
Journal:  Mamm Genome       Date:  2006-07-14       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.